Title |
REVIEW] Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease |
Author |
Taekil Eom1, Yong Sung Kim2, Chang Hwan Choi3, Michael J. Sadowsky4,5,6, and Tatsuya Unno1,7* |
Address |
1Subtropical/tropical Organism Gene Bank, Jeju National University, Jeju 63243, Republic of Korea, 2Department of Gastroenterology, Wonkwang Digestive Disease Research Institute, Wonkwang University Sanbon Hospital, Gunpo 15865, Republic of Korea, 3Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul 06974, Republic of Korea, 4BioTechnology Institute, University of Minnesota, St. Paul, Minnesota 55108, USA, 5Department of Soil, Water, and Climate, University of Minnesota, St. Paul, Minnesota 55108, USA, 6Department of Plant and Microbial Biology, University of Minnesota, St. Paul, Minnesota 55108, USA, 7Faculty of Biotechnology, School of life sciences, SARI, Jeju National University, Jeju 63243, Republic of Korea |
Bibliography |
Journal of Microbiology, 56(3),189–198, 2018,
|
DOI |
10.1007/s12275-018-8049-8
|
Key Words |
dysbiosis, gut microbiota, inflammatory bowel
disease, probiotics, prebiotics, short chain fatty acids |
Abstract |
Inflammatory bowel disease (IBD) is a result of chronic inflammation
caused, in some part, by dysbiosis of intestinal
microbiota, mainly commensal bacteria. Gut dysbiosis can
be caused by multiple factors, including abnormal immune
responses which might be related to genetic susceptibility,
infection, western dietary habits, and administration of antibiotics.
Consequently, the disease itself is characterized as
having multiple causes, etiologies, and severities. Recent studies
have identified > 200 IBD risk loci in the host. It has been
postulated that gut microbiota interact with these risk loci
resulting in dysbiosis, and this subsequently leads to the development
of IBD. Typical gut microbiota in IBD patients
are characterized with decrease in species richness and many
of the commensal, and beneficial, fecal bacteria such as Firmicutes
and Bacteroidetes and an increase or bloom of Proteobacteria.
However, at this time, cause and effect relationships
have not been rigorously established. While treatments
of IBD usually includes medications such as corticosteroids,
5-aminosalicylates, antibiotics, immunomodulators, and anti-
TNF agents, restoration of gut dysbiosis seems to be a safer
and more sustainable approach. Bacteriotherapies (now called
microbiota therapies) and dietary interventions are effective
way to modulate gut microbiota. In this review, we summarize
factors involved in IBD and studies attempted to treat IBD
with probiotics. We also discuss the potential use of microbiota
therapies as one promising approach in treating IBD.
As therapies based on the modulation of gut microbiota becomes
more common, future studies should include individual
gut microbiota differences to develop personalized therapy
for IBD. |